S 488210

Drug Profile

S 488210

Alternative Names: RSC-488210; S-488210

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator OncoTherapy Science
  • Developer Shionogi
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer

Most Recent Events

  • 31 Aug 2015 S 488210 is still in phase I/II trials for Head and neck cancer in Belgium and Germany
  • 13 Jun 2012 Phase-I/II clinical trials in Head and neck cancer (Locally recurrent, Second-line therapy or greater, Inoperable/Unresectable) in Belgium and Germany (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top